In conclusion, our study demonstrates that the copy number of PPP1R12A could independently predict recurrence and overall survival of stage III colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy. This evidence concerns the gene PPP1R12A and colorectal cancer.